Lytix Biopharma: Invitation to the Q3 2026 Results Presentation

Oslo, Norway, November 6, 2026 – Lytix Biopharma ASA ("Lytix" or the "Company") will release its third quarter 2026 financial results on Friday, November 13, 2026.

Join us for a live webcast presentation featuring CEO Øystein Rekdal, CFO Gjest Breistein and CMO Karim Benhadji where they will discuss the results and provide key insights.

Date: Friday, November 13, 2026
Time: 14:00 CET

Q&A Session:
We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation.

Webcast Details:
The presentation and Q&A session will be conducted in English. You can view the live event by registering here: http://qcnl.tv/p/7YpgKFsTuKpxolSOKBNeSw

Missed the Live Session?
A recording of the presentation will be available shortly after the event on our financial reports page: http://www.lytixbiopharma.com/investors/reports-and-presentations/financial-reports

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com.